BMRN — BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical (BMRN) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: $3.22 billion for 2025, a 13% increase year-over-year.
• Q4 Revenues: $875 million, representing a 17% year-over-year growth.
• Voxzogo Revenue: Increased by 26% in 2025, totaling $927 million; Q4 growth was 31%.
• Enzyme Therapies Revenue: Grew by 9% year-over-year, with notable contributions from Palynziq (22% growth) and Vimizim (7% growth).
• Non-GAAP EPS: $3.15 for 2025, with a 34% increase in underlying business earnings per share.
• Operating Cash Flow: $828 million, a 45% increase from 2024.

2. Strategic Updates and Business Highlights

• Acquisitions: BioMarin is integrating assets from Inozyme (BMN 401 for ENPP1 deficiency) and Amicus (Galafold for Fabry disease, Pombiliti and Opfolda for Pompe disease), expected to close in Q2 2026.
• Pipeline Expansion: Anticipated pivotal data for BMN 333 (long-acting CNP therapy for achondroplasia) and Voxzogo's potential expansion into hypochondroplasia treatment.
• Operational Excellence: Continued focus on enhancing global capabilities and commercial reach, with a strong emphasis on patient identification and treatment access.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenues between $3.325 billion and $3.425 billion, excluding contributions from Amicus products.
• Voxzogo Revenue: Projected between $975 million and $1.025 billion, reflecting high single-digit growth.
• Enzyme Therapies Revenue: Expected between $2.225 billion and $2.275 billion.
• Non-GAAP EPS Guidance: Anticipated in the range of $4.95 to $5.15, factoring in costs related to the Amicus acquisition.

4. Bad News, Challenges, or Points of Concern

• Withdrawal of Roctavian: BioMarin withdrew Roctavian from the market, resulting in a $240 million charge, impacting GAAP earnings.
• Market Access Challenges: Anticipated lower royalty revenues from KUVAN and Roctavian in 2026, presenting a headwind to overall revenue growth.
• Competitive Pressures: Concerns regarding new entrants in the achondroplasia market could impact Voxzogo's growth trajectory, though management remains confident in its established safety and efficacy data.
• Quarterly Revenue Volatility: Q1 2026 is expected to be the lowest revenue quarter, influenced by large order timing and potential inventory adjustments.

5. Notable Q&A Insights

• Market Dynamics: Discussion on the potential impact of new oral therapies for achondroplasia and the likelihood of patient switching from Voxzogo, with management emphasizing the importance of long-term safety and efficacy data.
• BMN 333 Expectations: Clarification on the Phase III study design and the potential for BMN 333 to establish a best-in-disease profile, with flexibility in adjusting study parameters based on interim results.
• Hypochondroplasia Launch: Anticipated regulatory submissions for hypochondroplasia treatment later in 2026, with immediate revenue impact expected post-approval.
• Integration of Amicus: Management expressed confidence in leveraging existing commercial infrastructure to integrate Amicus products effectively, enhancing the enzyme therapies portfolio.

Overall, BioMarin's Q4 2025 earnings call highlighted strong financial performance, strategic growth initiatives through acquisitions, and a positive outlook for 2026, tempered by challenges related to market dynamics and competitive pressures.